Navigation Links
Campbell Alliance Announces Windhover Top 10 Oncology Projects for 2011
Date:11/29/2011

RALEIGH, N.C., Nov. 29, 2011 /PRNewswire/ -- Campbell Alliance, an inVentiv Health company and the leading management consulting firm specializing in the pharmaceutical and biotech industry, today announced the assets chosen for the 2011 Top 10 Most Licensable Oncology Projects to Watch.  Selected projects will be discussed in more detail at the upcoming Windhover Therapeutic Area Partnerships conference (http://www.tapartnerships.com) in Boston, November 30 through December 2.

Narrowed from a field of over 1,700 oncology assets using a strict set of judging criteria, the selected projects represent what are considered the most attractive licensable oncology opportunities the industry has to offer.  Specifically, the selection team focused on what are considered "hot areas" in oncology:  those with transformational, nascent therapies where the potential for differentiation is high.  Conjugated antibody, cancer metabolism, and immuno-oncology technologies dominated the list this year.

"Our approach this year was to look at differentiated molecular pathways and technologies," said Jonathon Fendelman, Senior Practice Executive at Campbell Alliance.
"While these targeted approaches tend to address smaller patient populations initially, a great deal of potential exists for add-on indications, which makes them attractive licensing opportunities.  Further, strong differentiation raises the likelihood of reimbursement post-approval, which is key in an increasingly payer-driven market."
2011 Top 10 Most Licensable Oncology Projects to Watch
CompanyAsset/CompoundLocationWebsiteAdvaxis

ADXS-HPV

US/New Jersey

www.advaxis.comAltor

ALT-801

US/Florida

www.altorbioscience.comAveo

Ficlatuzumab

US/Massachusetts

www.aveopharma.comBiotest AG

BT-062

Germany

www.biotest.comCelldex

CDX-011

US/Massachusetts

www.celldextherapeutics.comEndocyte

EC145

US/Indiana

www.endocyte.comImmunoCellular Therapeutics

ICT-107

US/California

www.imuc.comImmune System Therapeutics 

MDX 1097

Australia

www.istl.com.auNeogenix Oncology

Ensituximab/NPC-1C

US/New York

www.neogenix.comRuga

STF-31

US/California

www.rugacorp.comCampbell Alliance has served as advisor for the oncology track of the Therapeutic Area Partnerships event since 2007.  More information on Campbell Alliance's Top 10 Oncology Projects can be found at http://www.campbellalliance.com/OncTop10.

Windhover originally announced the full list of companies selected as part of the Therapeutic Area Partnerships conference on November 1.  The list included assets from each of several therapeutic areas:  cardiovascular/metabolic, oncology, neuroscience, infectious diseases, and inflammatory/autoimmune, plus a "hot space" category, including ophthalmology, orphan diseases, and women's health.

About Campbell Alliance
Campbell Alliance is the Consulting business segment of inVentiv Health, a leading global provider of best-in-class clinical, commercial, and consulting services to companies seeking to accelerate performance.  Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry.  The firm's clients include all of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Pricing and Market Access, Medical Affairs, and Sales.  From its locations in Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston, Philadelphia, New York City, Atlanta, and Zug, Switzerland, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit http://www.campbellalliance.com.   

 

 CONTACT:James Forte

Director, Public and Media Relations

Campbell Alliance

919-844-7100, extension 7195

jforte@campbellalliance.com
'/>"/>

SOURCE Campbell Alliance
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WorldHeart Appoints Dr. John Campbell Woodard as Senior Vice President of Scientific Affairs
2. Tunnell Consulting Forms Strategic Alliance With Ireland-Based Campbell Informatics
3. Campbell Alliance Announces Executive Promotions and Organizational Changes
4. Nader Naeymi-Rad Appointed CEO of Campbell Alliance
5. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
6. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
7. Lung Cancer Alliance Commends NCCN on Screening Guidelines
8. Lung Cancer Alliance Hails Announcement of New Erbitux(R) Data
9. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
10. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
11. Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2017 Halo Labs announces the European launch of their ... HORIZON at MIBio 2017 in Cambridge, U.K ... matter in biopharmaceutical samples with unprecedented speed and sensitivity while using ... Backgrounded Membrane Imaging. ... subvisible particle analysis system ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host ... webcast on Friday, November 3, 2017, beginning at 7:00 ... approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... performance and guidance for 2018, Hill-Rom executives will also ... performance, and long-range financial outlook through 2020. ...
(Date:9/27/2017)... their devotion to personalized service, SMP Pharmacy Solutions announces their ... South Florida Business Journal,s 50 Fastest-Growing Companies, and listed for ... specialty pharmacy has found its niche.  To that end, the ... by SFBJ as the 2017 Power Leader in Health Care. ... award in October, Bardisa said of the three achievements, "It,s ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
Breaking Medicine News(10 mins):